Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3  by Boehm, Marcus F. et al.
Research Paper 265 
Novel nonsecosteroidal vitamin D mimics exert VDR-modulating 
activities with less calcium mobilization than 
1,25=dihydroxyvitamin D, 
Marcus F Boehml, Patrick Fitzgerald*, Aihua Zou*, Marc G Elgort*, Eric D 
Bischoff*, Lora Mere3, Dale E Mais4, Reid P Bissonnette*, Richard A Heyman*, 
Alex M Nadzanl*, Melvin Reic hman3 and Elizabeth A Allegretto* 
Background: The secosteroid 1,25-dihydroxyvitamin D, (1,25(OH),D,) acts 
through the vitamin D receptor (VDR) to elicit many activities that make it a 
promising drug candidate for the treatment of a number of diseases, including 
cancer and psoriasis. Clinical use of 1,25(OH),D, has been limited by 
hypercalcemia elicited by pharmacologically effective doses. We hypothesized 
that structurally distinct, nonsecosteroidal mimics of 1,25(OH),D, might have 
different activity profiles from vitamin D analogs, and set out to discover such 
compounds by screening small-molecule libraries. 
Results: A his-phenyl derivative was found to activate VDR in a transactivation 
screening assay. Additional related compounds were synthesized that mimicked 
various activities of 1,25(OH),D,, including growth inhibition of cancer cells 
and keratinocytes, as well as induction of leukemic cell differentiation. In 
contrast to 1,25(OH),D,, these synthetic compounds did not demonstrate 
appreciable binding to serum vitamin D binding protein, a property that is 
correlated with fewer calcium effects in viva. Two mimics tested in mice 
showed greater induction of a VDR target gene with less elevation of serum 
calcium than 1,25(OH),D,. 
Conclusions: These novel VDR modulators may have potential as therapeutics 
for cancer, leukemia and psoriasis with less calcium mobilization side effects 
than are associated with secosteroidal 1,25(OH),D, analogs. 
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Introduction 
The active form of vitamin D,, 1,25-dihydroxyvitamin 
D, (l,ZS(OH),D,), is a secosteroid that has long been 
recognized as a major regulator of calcium homeostasis 
and bone development and remodelling [1,2]. Since the 
early 1980s 1,25(OH),D, has been shown to be a potent 
differentiator of leukemic cells [3-51 and a growth inhibitor 
of various types of cancer cells, including those of the 
prostate, breast and colon [6-81. l,ZS(OH),D, has also 
been shown to have immunosuppressive effects [9,10], 
some of which have been borne out in animal models 
of Lupus, autoimmune diabetes and multiple sclerosis 
[ll-131. The molecular mechanism of 1,25(OH),D, is 
known to be through binding to its intracellular receptor, 
the vitamin D receptor (VDR). This binding results in 
heterodimer formation with retinoid X receptor (RXR), 
which enables high-affinity binding to vitamin D respon- 
sive element (VDRE) sequences within, and subsequent 
transcriptional activation of, vitamin D target genes such 
as the bone proteins osteocalcin and osteopontin, and a 
metabolic enzyme, 25-hydroxyvitamin D3-24-hydroxylase 
(24(OH)ase) [14-151. 
The activity of 1,25(OH)2D, as a modulator of growth and 
an inducer of differentiation of a variety of cancer cell 
types both in vitro [l&18] and in animal models [19-231 
suggested a potential clinical application of this hormone in 
cancer, as well as for psoriasis [24], a disease that has both 
hyperproliferative and autoimmune components. However, 
the normal calcium-mobilization function of 1,25(OH),D, 
is increased as the dosage is increased to pharmacological 
levels, leading to hypercalcemia (elevated serum calcium) 
in animal and in human subjects, which has limited the 
usefulness of 1,25(OH),D, as a drug. Recently, however, 
chemical modification of 1,25(OH),D, has yielded a number 
of secosteroidal analogs that have a greater ratio of desir- 
able effects to unwanted calcium mobilization effects [25]. 
One of these analogs, MC903 or Dovonex@, is currently 
in use as a topical treatment for mild to moderate psoria- 
sis [26]. Although a number of 1,25(0H),D, analogs have 
shown some separation of antiproliferative activities from 
calcium-raising effects, this separation does not seem to be 
sufficient for long-term oral drug therapy of conditions 
such as cancers and severe psoriasis, and, therefore, there is 
a need for improved compounds. All compounds known to 
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Structures of vitamin D mimic compounds. LGl90176 and LG190178 
are mixtures of stereoisomers. 
date that activate VDR are analogs of l,Z(OH),D,. We 
hypothesized that nonsecosteroidal VDR ligands might 
display different profiles of activity and metabolism than 
do secosteroidal l,ZS(OH),D, analogs, including less cal- 
cemic properties, which might render them attractive as 
both topical and oral pharmaceuticals for treating a 
variety of diseases. 
This hypothesis was based in part on the success that 
nonsteroidal androgen receptor (AR) and estrogen recep- 
tor (ER) modulators have had as drugs. Although the 
natural AR and ER ligands are steroids (dihydrotestoster- 
one and 17-B-estradiol, respectively), nonsteroidal com- 
pounds have been synthesized that modulate the activity 
of these receptors and show enhanced tissue selectivity in 
comparison to the steroids. The AR ligands flutamide 
(Eulexin@) and bicalutamide (Casodex@) are currently used 
to treat prostate cancer and the ER modulator tamoxifen 
(Nolvadex@) is the drug of choice for ER-positive breast 
cancer. Additionally, a promising new nonsteroidal-ER 
modulator drug, raloxifene (Evista@), is now available and 
several other selective nonsteroidal-ER ligands are in the 
drug pipeline for use in hormone replacement therapy 
and breast cancer. 
Described herein are novel nonsecosteroidal activators of 
VDR (Figure 1). These compounds mimicked various 
l,ZS(OH),D, activities in vitro, such as interaction with 
VDR, VDR-dependent transcriptional activation, inhibi- 
tion of proliferation of human cancer cells and primary 
human keratinocytes and monocytic differentiation of 
HL60 leukemic cells. These compounds did not bind to 
serum vitamin D binding protein (DBP), a property that 
has been previously correlated with less calcemic poten- 
tial is viva [27]. Additionally, these compounds induced 
RNA levels of a VDR target gene, kidney 24(OH)ase, in 
rodents to a greater extent than l,ZS(OH),D, did, with less 
increase in serum calcium than exhibited by l,Z.5(0H)ZD,. 
Therefore, these structurally novel compounds might have 
promise as therapeutics for a wide variety of diseases with 
less severe calcium-related side effects than secosteroidal 
vitamin D analogs. 
Results 
Transactivational properties of 1,25(OH),D, and vitamin D 
mimics 
In an attempt to identify nonsecosteroidal activators of 
VDR, compound libraries were screened in a cotransfec- 
tion-cotransactivation (CTF) assay in which Hep G2 cells 
were transfected with a luciferase reporter vector driven 
by one copy of a VDRE from the h24(OH)ase pro- 
moter (VDRE-AMTV-LUC [28]) with or without a VDR 
expression vector (pRShVDR). In this assay l,ZS(OH),D, 
induced luciferase activity in the presence of pRShVDR 
(Figure Z), but not without the expression plasmid 
(data not shown), indicating that the response was VDR- 
dependent. 1,25(OH)ZD, elicited an approximately lo-fold 
induction of luciferase with a potency (EC,,,) of 2-5 nM 
(Figure 2, Table 1). One compound, a &-phenyl deriva- 
tive designated LG190090 (Figure l), induced luciferase 
activity -ninefold in a VDR-dependent manner with an 
EC,, of -2.5 @I (Figure 2). Several related analogs were 
synthesized around this hit, some of which are shown in 
Figure 1, that display increased potency in the CTF assay 
(Figure 2). Chemical modifications at the bridgehead of 
LG190090 to a cyclohexyl (LG190119) or diethyl (LG190155, 
LG190176, and LG190178) group led to increased potency 
in CTF assays (Table l), and additional polar groups such 
as hydroxyl moieties (LG190178) also resulted in increased 
potency in CTF assays and increased binding affinity for 
VDR in vitro (see below and Table 1). Each of these com- 
pounds required the presence of VDR expression vector to 
induce VDRE-driven reporter activity (data not shown). 
Compound efficacies were 80-100% of 1,25(OH),D, and 
potencies ranged from 2.2 @I to 40 nM (Figure 2, Table 1). 
None of these compounds showed cross-reactivity with 
various other intracellular receptors in cotransactivation 
assays utilizing reporters driven by their respective response 
elements, including RXRs and retinoic acid receptors 
(RARs; data not shown). These results indicated that these 
compounds stimulated the VDRE-driven reporter by acti- 
vation of VDR and were henceforth termed vitamin D 
mimics, because they resembled l,ZS(OH),D, functionally 
without sharing its structure. 
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Vitamin D mimics induce transcription from a VDRE-driven reporter 
vector in a VDR-dependent manner in cotransfection-cotransactivation 
assays. pRShVDR was cotransfected along with VDRE-AMTV-LUC 
into Hep G2 cells and cells were subsequently treated with 
1,25(OH),D, or vitamin D mimics in various concentrations. Luciferase 
activity was measured and values werls normalized for transfection 
efficiency with P-galactosidase values 
VDR-binding characteristics of vitamin D mimics 
To determine if the vitamin D mimics bound directly to 
VDR in vitro, l&and-binding assays were performed. Unla- 
beled l,‘ZS(OH),D, competed with [3H]-1,25(OH),D, for 
binding to yeast-expressed hVDR with an equilibrium dis- 
sociation constant (Ki) of 0.5 nh4. Many of the vitamin D 
mimics that displayed lower potency (EC,, >500 nM) in 
Hep G2 cell cotransactivation assays did not compete with 
[3H]-1,25(OH),D, in VDR-binding assays performed under 
equilibrium conditions in vitro, whereas the more potent 
mimics in the cell-based assay did demonstrate binding to 
Table 1 
VDR under these conditions (Table 1 and data not shown). 
For example, LG190178 (EC,, -40 nM in the Hep G2 cell 
CTF assay) showed a Ki value of 150nM in the VDR- 
binding assay (Table 1). This observation was true for most 
mimics synthesized; as compound potency increased in 
the Hep G2 cell cotransactivation assay, VDR binding was 
observed in vitro. Therefore, the VDR-dependent cell- 
based assay was more sensitive than the in vitro VDR equi- 
librium-binding assay in detection of VDR activators of this 
class. Additionally, none of the vitamin D mimics displayed 
any binding to RXRs or RARs (data not shown). 
We hypothesized that detection of VDR binding of the 
less potent vitamin D mimic compounds under equilib- 
rium conditions in a competition binding assay with [3H]- 
l,Z(OH),D, was precluded by the fast on-rate and slow 
off-rate of the high-affinity ligand l,ZS(OH),D,. To test this, 
LG190119, LG190155 or LG190178 was preincubated with 
VDR overnight prior to incubation with [3H]-1,25(OH)2D, 
for various time periods between 2 min and 1 h to deter- 
mine if the compounds would inhibit binding of [3H]- 
l,ZS(OH),D, to VDR in comparison with preincubation 
of VDR with vehicle alone. LG190178, which showed 
demonstrable binding to VDR under equilibrium con- 
ditions (Table l), also inhibited the binding of [3H]- 
l,ZS(OH),D, to VDR in the preincubation assay (Table 2). 
Percent inhibition of [3H]-1,25(OH),D, binding to VDR by 
LG190178 ranged from 94% at 2 min to 97% at equilibrium 
(20 h). Preincubation of VDR with LG190119 or LG190155 
also resulted in decreased binding of [3H]-1,25(OH)2D, to 
VDR at short time intervals in comparison with preincuba- 
tion of VDR without compound, and this percent inhi- 
bition decreased with increased incubation time with 
[3H]-1,25(OH),D3 (Table 2). At 2 min LG190119 elicited 
26.5% inhibition of [3H]-1,25(OH),D3 binding to VDR and 
LG190155 preincubation led to 32% less binding. These 
percentages decreased at subsequent time points, showing 
1516% inhibition at 60 min, and essentially no inhibition 
Activity of selected vitamin D mimics in in vitro and cell-based assays. 
CTF VDR Binding LNCaP BrdU HL60 NBT NHEK BrdU DBP Binding 
Compound EC,, WA)* K, (nM)+ EC,, WI)* EC,, bWJ EC,, WV IC,, (nM)n 
LG 190090 2500 >10000 3000 10000 ND >10000 
LG190119 2200 >10000 2000 2000 500 >10000 
LG190155 600 >10000 300 800 500 >10000 
LG190176 60 >10000 100 150 200 >10000 
LG190178 40 150 20 30-50 30-50 >10000 
1,25(OW,D, 2-5 0.5 2 8-10 1 O-30 200 (h); 40 (r) 
*EC,, values determined by cotransfection-transactivation assays values determined by nitroblue tetrazolium assay of differentiation of 
using pRShVDR and VDRE(l)-AMTV-LUC in Hep G2 cells. +Ki HL60 human leukemia cells. #EC&, values determined by growth 
(equilibrium dissociation constant) values determined by in vitro inhibition of normal human epidermal keratinocytes by BrdU 
competition binding to yeast-expressed hVDR expressed versus incorporation. “I&,, values determined by in vitro competition binding 
[3Hl-1 ,25(OH),D,. *EC,, values determined by growth inhibition of to human (h) or rat (r) serum vitamin D binding protein versus 
LNCaP human prostate cancer cells by BrdU incorporation. SEC,, [3HI-25(0H)DS. ND, not determined. 
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Table 2 
Percent inhibition of [3HI-1,25(OH),D3 binding to VDR in vitro by preincubation with various compounds. 
Compound preincubation 
Time of incubation with L3H]-l ,25(OH),D, 
Compound concentration* 2 min 10min 30 min 60 min 20 h 
LG190119 10pM 26.5 f 3.5+ 21 f1.4 16 -f 2.8 16.5 + 6.4 1.3 + 0.4 
LG190155 1OpM 32 f 2.8 18 + 4.2 16 f 2.8 15rt1.4 3fl 
LG190178 IOpM 94 k 2.1 96+1 99.5 k 0.7 lOOk0 9721.5 
1250-&D, 1 PM 100 100 100 100 100 
*Preincubation of yeast-expressed hVDR (2.5 pg total soluble protein L3Hl-l ,25(OH),D, binding to VDR in the absence of compound 
extract) with compounds was for 20 h prior to addition of 0.34 nM 
13HI-1 ,25(OH),D,. +Percent inhibition determined by the ratio of 
relative to inhibition of [3H]-1 ,25(OH),D, binding to VDR by unlabeled 
f3Hl-1 ,25(OH),D, binding to VDR in the presence of compound to 
1,25(OH),D, at each time point (average of two individual experiments 
with each point assayed in triplicate). 
at 20 h (equilibrium conditions), as expected. Therefore, compounds do interact with VDR, as demonstrated by their 
although direct binding ofVDR by LG190119 and LG190155 ability to inhibit [3H]-1,25(OH)2D3 from binding to VDR 
was not detectable under equilibrium conditions, both during short time intervals. 
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Activity of vitamin D mimics in SK-BR3 breast cancer cell 
and LNCaP prostate cancer cell growth assays 
Growth of SK-BR-3 human breast cancer cells has been 
shown previously to be inhibited by 1,25(OH),D, [29]. 
Using BrdU incorporation assays, l,ZS(OH),D, had an EC,,, 
of 30 nM and -90% efficacy in inhibiting DNA replication 
in these cells (Figure 3). The vitamin D mimics also inhib- 
ited the growth of these cells, displaying 50-100% efficacy 
(Figure 3). The rank order of potencies of the mimics in 
inhibiting DNA replication in SK-BR3 cells agreed with 
those observed in the cotransactivation assay (Table 1). 
The SK-BR-3 cell number also decreased upon treatment 
with l,ZS(OH),D, or vitamin D mimics (data not shown). 
Growth of LNCaP human prostate cancer cells has also 
been shown to be inhibited by l,ZS(OH),D, [X,18], and 
these cells were also tested for their response to the vitamin 
D mimics. l,Z(OH),D, was a potent growth inhibitor of 
these cells with an EC,, of 2 nM and -95% efficacy in the 
BrdU assay (Table 1). The vitamin D mimics inhibited 
BrdU incorporation in these cells with 60-100% efficacy 
and showed a rank order of potency values that were similar 
to those obtained in the Hep G2 cell CTF assays and SK- 
BR-3 cell growth assays (Table 1, Figure 3). Therefore, the 
vitamin D mimics, like l,Z(OH),D,, were able to inhibit 
the proliferation of two human cancer cell lines in culture. 
Figure 3 
Vitamin D mimics inhibit the growth of SK-BR-3 human breast cancer 
cells in culture. SK-BR-3 cells were plated at 3000 cells per well in 
96-well plates. (a) 1,25(OH),D,, LGl90119 or LG190155, or 
(b) 1,25(OH),D,, LGl90176 or LG190178 were added in ethanol 
vehicle in media at 7 concentrations between 1 O-5 and IO-J1 M. After 
3 days, BrdU incorporation ELISA were performed and the calorimetric 
reaction was stopped and absorbance was measured at 450 nm. 
Vehicle average is denoted by a solid diamond on the y axis. 
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Figure 4 
Vitamin D mimics induce differentiation of 
HL60 human leukemic cells to macrophages. 
HL60 cells were grown and plated as 
described in the Materials and methods 
section. Ligands at various concentrations 
were added to the cells in ethanol vehicle and 
incubation proceeded for 5 days. Cells were 
harvested and CD1 4 analyses via FACS were 
performed. V, vehicle; 1,25D,, 1,25(C)H),D,; 
cRA, 9-cis retinoic acid; LGSO, LG190090; 
LG119,LG190119;LG155,LG190155; 
LG176, LG190176; LGI 78, LGI 90’178. 
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Differentiation of HL60 cells into macrophages by 
vitamin D mimics 
l,ZS(OH),D, is a known differentiator of HL60 human 
leukemia cells into macrophages/monocytes [S]. Using 
nitroblue tetrazolium (NBT) [5,30] and CD14 (a specific 
marker for macrophages/monocytes) FACS [31] assays, 
l,ZS(OH),D, induced differentiation of HL60 cells with 
an EC,, of 8-10 nM, and -100% efficacy was achieved 
with 100 nM 1,‘25(OH),D, (Figure 4). Even the least 
potent vitamin D mimics were efficient inducers of HL60 
cell differentiation as assessed by both NBT reduction 
(Table 1) and CD14 induction (Figure 4). LG190090 had 
an EC,, of 8 pM in these assays (Table 1, Figure 4), with 
an efficacy of -70% differentiation at 10 @I (Figure 4). 
The more potent mimics differentiated the cells with 
EC,, values of 30-150 nM and >90% efficacy (Table 1, 
Figure 4). Retinoids are also known to induce differen- 
tiation of HL60 cells, however, this differentiation is to 
granulocytes, which do not express CD14. As shown in 
Figure 4, 100 nM 945 retinoic acid (cRA) did not induce 
CD14 expression in these cells, although NBT was reduced 
(data not shown). Therefore, the vitamin D mimics differ- 
entiated HL60 cells down the macrophage pathway, indi- 
cating a VDR-dependent mechanism. 
Vitamin D mimics growth inhibit and change the 
morphology of primary human keratinocytes 
Treatment of normal human epidermal keratinocytes for 
3 days with 1,25(OH),D, resulted in inhibition of BrdIJ 
incorporation with an EC,,, value of -30 nM (Table l), in 
agreement with previous work [32], and treatment for 7 days 
markedly changed the morphology of the cells (Figure 5), 
as reported previously [33]. The vitamin D mimics also 
inhibited the growth of the keratinocytes (Table 1) with 
rank order of potencies in agreement with those from other 
assays (Table 1, Figures 2-4) and elicited morphological 
changes, including the formation of spindle-like structures 
(Figure 5) that have been previously demonstrated with 
1,25(OH),D, [33]. LGD1550, a potent RAR-selective ligand 
also inhibited the growth of keratinocytes (data not shown); 
however, the spindle-like structures were not observed 
(Figure 5). The vitamin D mimics described herein, there- 
fore, share many activities and specificities of 1,25(OH),D, 
in a variety of in vitro cell-based assays. 
Vitamin D mimics do not bind to rat or human serum DBP 
The ability of various 1,25(OH),D, analogs to bind DBP 
has been associated with their ability to raise serum 
calcium in viva, whereas analogs with lower affinities for 
DBP showed lowered calcium potential in animal models 
[27]. To examine the DBP-binding characteristics of these 
vitamin D mimics, rat or human serum was incubated with 
[AH]-25(OH)D, with and without unlabeled competitor 
ligands. IC,, values of ZS(OH)D, (the endogenous precur- 
sor of 1,25(OH)2D3) for rat and human DBP were 1 nM 
and 2 nM, respectively; IC,, values of 1,25(OH),D, for 
rat and human DBP were 30-50 nM and 200 nM, respec- 
tively (in agreement with values published previously 
[27,34]). Using this DBP-binding assay, none of the vitamin 
D mimics tested bound appreciably to either rat or human 
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Figure 5 
Vitamin D mimics induce morphological 
changes in normal human epidermal 
keratinocytes. Keratinocytes were grown and 
treated as described in the Materials and 
methods section. Cells were incubated with 
ligands (as denoted in the figure) for 7 days, 
with media change and compound 
replenishment on days 2 and 4. 
DBP, showing IC,, values greater than 10 PM (Table 1). 
Therefore the DBP-binding properties of the vitamin D 
mimics implied that they might be less calcemic in z?ivo 
than l,ZS(OH),D,. 
Vitamin D mimics induce a VDR target gene in viva, with 
less serum calcium increase than 1,25(OH),D, 
In order to test the oral bioavailability and activity of the 
vitamin D mimics in viva, LG190119 and LG190155 were 
administered in sesame oil to mice by gavage for 3 or 5 con- 
secutive days at various concentrations. l,Z(OH),D, was 
tested at 2, 5 and 15 pg/kg, LG190119 was tested at 10 and 
30 mg/kg, and LG190155 was tested at 0.1 and 0.5 mg/kg. 
l,ZS(OH),D, induced kidney 24(OH)ase RNA, as assessed 
by Northern analysis, .5.7-fold after 3 days in one experi- 
ment and ZO- to Z-fold after 5 days in a second assay 
(Table 3). LG190119 induced kidney 24(OH)ase RNA lo- 
to 13-fold after 3 days and 30- to 54-fold after 5 days treat- 
ment, whereas LG190155 induced 24(OH)ase 6-fold after 3 
days treatment (Table 3). Although the dose of 15 pg/kg 
l,ZS(OH),D, caused significant hypercalcemia after 3 days, 
the 2 pg/kg dose and 5 pg/kg dose slightly elevated calcium 
after 5 days, with the 5 pg/kg dose being significantly differ- 
ent from vehicle. In-depth toxicity studies were not carried 
out, however, weight loss was observed in each group of 
animals treated with l,ZS(OH),D, for both 3 and 5 days, 
and with the higher dose of LG190119 after 5 days of treat- 
ment (Table 3). The ratio of target gene induction to serum 
calcium concentration was greater with LG190119 or 
LG190155 than it was with l,ZS(OH),D, (Table 3), indicat- 
ing greater separation of these two in cjuo activities with the 
vitamin D mimics than with l,ZS(OH),D,. These data indi- 
cate that compounds of this structural class exhibit some of 
the same desirable biological actions of l,ZS(OH),D,, with 
less calcemic activity, and, therefore, might represent a new 
class of VDR modulators with potential clinical utility for 
treating a variety of diseases. 
Discussion 
The VDR is a nuclear receptor that has been known to 
be activated only by its endogenous secosteroidal ligand, 
l,ZS(OH),D,, or synthetic secosteroidal analogs that are 
structurally very similar to 1,25(OH)2D,j. In an attempt to 
identify structurally distinct, nonsecosteroidal activators 
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Table 3 
Analysis of VDR target gene regulation and calcemic potential of vitamin D mimics in mice. 
Compound Dose 
Kidney 
24(OH)ase* 
Serum 
Cal++ 
24(OH)ase/ 
Ca*+ 
24(OH)ase/ 
Ca2+ Increase 
% Weight 
change* 
3-day treatment (female BALB/c) 
Vehicle 
1,25KW,D, 15 Mb 5.7 
LGl90119 10 mglkg 13.5 
LG190119 30 mglkg 10.6 
LG190155 0.1 mg/kg 6.0 
LG190155 0.5 mglkg 6.0 
5-day treatment (male BALBlc) 
Vehicle 
1,25(OW,D, 2 w/kg 20.8 
1,25(OW,D, 5 w/b 24.9 
LG190119 10 mg/kg 30.8 
LG190119 30 mg/kg 53.7 
*Mean fold induction versus vehicle corrected with GAPDH; error 
within groups was 15% (Northern analysis). +Normal mouse serum 
calcium range is 7.9-10.5 mg/dl. *Mean of the percent weight change 
8.3 f 0.5 +0.7 
>159 0.38 0.85 -12.05 
9.1 + 0.5 1.48 16.9 -1.6 
9.0 f 0.6 1.18 15.1 -2.9 
9.6 f 0.5 0.63 5.17 +1.7 
1 1.5 f 0.95 0.52 1.88 -1.5 
8.6 f 0.4 -1.5 
9.7 f 0.6 2.14 18.9 -9.95 
10.5 k 0.65 2.37 13.1 -12.85 
9.1 f0.2 3.38 61.6 -5.1 
10.1 If-o.5 5.31 35.8 -11.15 
per animal per group over time of study. %tatistically different than 
vehicle (ANOVA, p<O.Ol). 
of VDR, we utilized a high-throughput cotransfection- 
cotransactivation (CTF) assay to screen a small-molecule 
library. LJsing this assay, a compound was discovered that 
elicited VDR-dependent stimulation of a VDRE-driven 
luciferase reporter vector. This compound, a symmetrical 
his-phenyl derivative designated LG190090, was struc- 
turally unrelated to 1,25(OH),D, (see Figure 1). Although 
LG190090 was much less potent in CTF assays (EC,, 
-2.5 PM) than l,Z(OH),D, (EC,, -2-S nhl), it showed 
almost equal efficacy. Additional compounds structurally 
related to LG190090 were synthesized and many had activ- 
ity in the CTF assay, some of which displayed increased 
potency compared with the lead molecule (Table 1). 
Chemistry efforts (synthesis of related analogs) increased 
the potencies of the vitamin D mimic compounds more 
than lOO-fold. For example, one of the more potent 
compounds synthesized, LG100178, displayed an ECj, of 
-40 nM in the CTF assay, only ten times less potent than 
l,ZS(OH),D, but -100 times more potent than the original 
lead compound. 
Most of the vitamin D mimics that had relatively weak 
potency in the CTF assay (EC,, >SOO nM) did not 
compete with [3H]-1,25(OH),D3 in VDR ligand-binding 
in vitro assays under equilibrium conditions. However, 
compounds with EC,, values in CTF assays of <SO0 nM 
did bind directly to VDR in zlitro under these conditions 
(Table 1 and data not shown). For example, LG190178 
had a Ki value of 150 nM in this binding assay. Therefore, 
the cell-based CTF assay is a more sensitive assay than 
the binding assay for detection of compounds of this 
series, an observation that has been made for other 
intracellular receptor screening assays (data not shown). 
Although the less potent vitamin D mimics did not bind to 
VDR under equilibrium conditions in competition with 
[3H]-1,25(OH),D3, preincubation of VDR with LG190119 
or LG190155 resulted in a decreased amount of [3H]- 
l,ZS(OH),D, that bound to VDR at short time periods 
(Table Z), indicating that these compounds do interact 
with VDR. All of the compounds of this series showed 
lower EC,, values in cell-based assays than Ki values in 
VDR equilibrium ligand-binding in vitro assays. This is in 
contrast to l,ZS(OH),D,, which has a Ki of 0.5 nM for 
VDR and an EC,,, of 2-5 nM in the Hep G’Z cell CTF 
assay. This series of nonsecosteroidal vitamin D mimic 
compounds’ ratios of CTF activity to VDR-binding activ- 
ity in vitro is similar to secosteroidal vitamin D analogs, 
which do not bind well to serum DBP. Compounds that 
do not bind DBP show greater potency in cell-based assays 
(which utilize serum in the growth media) than com- 
pounds that do bind DBP, because more of the former 
type of compound may enter the cell because it bypasses 
DBP. Therefore, the ratios of CTF potencies to VDR 
equilibrium binding affinities implied that the vitamin D 
mimics do not bind DBP well. This was indeed the case, 
determined by direct measurement using an in vitro 
DBP-binding assay. DBP- binding ability of l,ZS(OH),D, 
analogs has been correlated with their increased ability to 
raise calcium levels in &vo [27]. 
The vitamin D mimics described herein exert many of the 
actions of l,ZS(OH),D,. They inhibit the growth of cancer 
cells, including those of LNCaP prostate cancer and SK- 
BR-3 breast cancer. The mimics induce differentiation of 
HL60 leukemic cells to macrophages, a VDR-dependent 
pathway. The vitamin D mimics also inhibit the growth of 
and induce morphological changes in human keratino- 
cytes, predictive assays for the utility of compounds in the 
treatment of psoriasis. The results of these cell-based in 
vitro assays imply that the vitamin D mimic compounds 
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might have therapeutic utility in diseases such as cancer, in, including cancers of the breast, colon and prostate, 
leukemia and psoriasis. The lack of appreciable DBP- psoriasis, autoimmune disorders and renal osteodystrophy, 
binding by the mimics predicted that these compounds without some of the liabilities of 1,Z5(0H)D3 or its struc- 
might be less calcemic than l,ZS(OH),D, in Z&IO and turally related analogs. Efficacy studies in rodent models of 
thereby not be limited in their usefulness in the clinic by cancer and other diseases are currently underway to further 
hypercalcemia side effects. explore the potential of this class of compounds as drugs. 
To test this hypothesis, the vitamin D mimics LG190119 
and LG190155 were administered to mice orally and their 
ability to regulate a VDR target gene and increase serum 
calcium levels were assessed. Kidney ZiF(OH)ase RNA 
was induced at each concentration of 1,25(OH),D, tested. 
Calcium was elevated within the normal range with the 
lower doses of l,ZS(OH),D, tested and increased beyond 
the normal range with the highest dose of l,ZS(OH),D,. 
LG190119 and LG190155 were orally bioavailable in mice 
as indicated by their ability to induce kidney 24(OH)ase 
RNA at both doses tested. LG190119 and LG190155 
induced higher levels of 24(OH)ase RNA compared with 
1,WOW2D3, while raising serum calcium to a lesser 
extent. LG190119 and LG19015.S therefore show some 
dissociation of biological actions from calcium potentia- 
tion side effects in viva and show promise as potential 
therapeutic agents. 
This series of nonsecosteroidal vitamin D mimics are the 
first known compounds, other than 1,25(OH),D,3 analogs, 
that activate VDR. These compounds share various activi- 
ties with l,ZS(OH),D,, both in cell-based assays and Zn 
vle?o, as discussed here. These activities are measures of 
genomic activites of l,ZS(OH),D,, that is, activities that 
occur through VDR in cell nuclei to modulate gene tran- 
scription. It will be interesting to test these compounds for 
their ability to elicit fast actions of 1,ZS(OH)2D3, activi- 
ties that are postulated to be VDR-independent. Although 
many activities of l,ZS(OH),D, were also observed to occur 
with the vitamin D mimics, one characteristic that the 
vitamin D mimics did not share with l,Z(OH),D, was the 
ability to bind to serum DBP. Lowered affinity for DBP has 
been correlated with lowered calcium-mobilization effects 
in animals [25,27] and may therefore predict separation of 
desirable effects from the calcium-mobilization activity that 
has limited the usefulness of calcitriol as a drug. Addition- 
ally, l,ZS(OH),D, and various analogs thereof have been 
shown to be metabolized by certain cells into compounds 
that are growth stimulatory (M.J. Campbell et al., and G. 
Brown (1998). Pro-proliferating effects of vitamin D, 
metabolites during differentiation of HL60 cells [abstract]. 
Proc. Am. Assoc. Cancer Res. 39, 276). Because nonseco- 
steroidal vitamin D mimics are not expected to be sub- 
strates for 24(OH)ase and other l,ZS(OH),D, metabolic 
enzymes, these types of undesirable effects would be less 
likely with the mimics. Therefore, these structurally novel 
nonsecosteroidal vitamin D mimic compounds might 
have utility in the treatment of a variety of diseases that 
l,ZS(OH),D, has been shown or postulated to be beneficial 
Significance 
We report here on the discovery of novel nonsecos- 
teroidal activators of the vitamin D receptor (VDR). We 
hypothesized that structurally distinct activators of 
VDR would have different activity profiles than its 
endogenous secosteroidal ligand, 1,25dihydroxyvitamin 
D, (1,25(OH),D,). This has been successfully demon- 
strated for nonsteroidal modulators of the androgen 
receptor (bicalutamide and flutamide) and the estrogen 
receptor (tamoxifen and raloxifene), which are cur- 
rently marketed for therapeutic use in prostate cancer, 
breast cancer and hormone replacement therapy. These 
nonsecosteroidal VDR modulators mimic many of the 
activities of 1,25(OH),D,. They interact with VDR in 
vitro, stimulate transcription from a VDR-response 
element in cotransfection assays in a VDR-dependent 
manner, inhibit the proliferation of human breast 
cancer cells (SK-BR31, prostate cancer cells (LNCaP) 
and primary keratinocytes, and induce monocytic differ- 
entiation of HL60 leukemic cells. Although these prop- 
erties of 1,25(OH),D, make it a promising therapeutic 
for human cancer, leukemia, psoriasis and other dis- 
eases, its use in the clinic has been limited because it 
causes hypercalcemia as pharmacologically effective 
doses are reached. Unlike 1,25(OH),D,, the vitamin D 
mimic compounds described here do not bind to serum 
vitamin D binding protein (DBP), a property that has 
been previously correlated with less calcemic potential 
in viva. Additionally, these compounds induced a VDR 
target gene in rodents to a greater extent than 
1,25(OH),D, and with less increase in serum calcium 
than exhibited by 1,25(OH),D,. Therefore, these struc- 
turally novel compounds might have promise as thera- 
peutics for a wide variety of diseases. 
Materials and methods 
Chemical synthesis 
The synthesis of analogs 4a, 4b, 6 and 8 is shown in Figure 6. Phenols 3a 
and 3b were synthesized by acid-catalyzed condensation of o-cresol with 
the appropriate ketones 2a and 2b. Alkyl ethers were prepared using a 
Williamson-type condensation between the phenols and the appropriate 
alkyl halides to give compounds 4a, 4b, 5 and 6 (6 is a racemic mixture). 
Treatment of phenol 5 with NaH and glycidol followed by hydride reduc- 
tion of the ketone gave trio1 8 as a mixture of diastereomers. 
I, l-Bis[4-(2-oxo-3,3-dimethylbutoxy)3- 
methylphenyl)]cyclohexane 4a (LG 190 119) 
To 5.0 g (46.3 mmol) of o-cresol 1 and 2.0 g of cyclohexanone 2a in 
20 ml of acetic acid was added 4 ml concentrated H,SO,. The reac- 
tion was stirred at room temperature for 3 days and poured over ice, 
followed by addition of 1:5 EtOAc:hexanes. The organic layer was sep- 
arated and washed (H,O, brine), dried (MgSO,) and concentrated. 
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Figure 6 
Synthesis of vitamin 0 mimics. 
AcOH 
HO OH 
1 2a R + R = cyclohexane 3a R + R = cyclohexane 
2b R=Et 3b R= Et 
NaH, OMF 
4a R + R = cyclohexane (LG190119) 
4b R = Et (LG190155) 
3b ” 
-cotm 
NaH, DMF yo$+po.~ :I,-*o$+poq 
0 
5 6 (LG190176) 
5 
= “-K-D$-$OH~~ ‘;:“&OpH Glycidol 
7 8 (LG190176) 
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Purification by silica gel chromatography (5% EtOAc/95% hexanes) 
resulted in 1.8 g (6.3 mmol) of phenol 3a (14% yield). ‘HNMR CDCI, d 
6.98 (d, J = 2.0 Hz, 2H, Ar-H), 6.95 (dd, J = 2 Hz, J = 8.6 Hz, 2H, Ar-H), 
6.64 (d, J = 8.6 Hz, 2H. Ar-H), 2.19 (s, 6H, Ar-CH3), 2.19 (m, 4H, 
2(-CH,-)), 1.27-l .52 (m, 6H. -CHP-CH,-CH,-). 
To 1 .O g (3.37 mmol) of dml 3a in 10 ml of DMF was added 306 mg 
(8.00 mmol) of NaH. After stirring for 5 min, 1 07 g (8.00 mmol) of 
chloropinacolone was added. The reaction mixture was stirred for a 
further 30 min followed by addition of H,O and EtOAc. The organic 
layer was separated and washed (H,O, brine), dried (MgSO,) and con- 
centrated. Purification by silica gel chromatography (10% EtOAc/SO% 
hexanes) resulted in 820 mg (1.66 rnmol) of 4a as a white powder 
(49% yield). ‘HNMR CDCI, d 7.09 (cl, J = 2.0 Hz, ZH, Ar-H), 6.96 (dd, 
J=Z.O Hz, J=8.6Hz, ZH, Ar-H), 6.51 (d, J= B.6Hz, ZH, Ar-H), 4.82 
(s, 4H, -CH,O-), 2.25 (s, 6H, Ar-CH,), 2.19 (m, 4H. P(-CH,-J), 1.27. 
1.52 (m, 6H, -CH2-CHZ-CH2-), 1.25 (s, 18H, t-but) 
3,3-Bis[4-(2-oxo-3,3-dimethylbutoxy)-3- 
methylphenyl)lpentane 4b (LG790755) 
Compound 4b was prepared (as a white powder) in a similar manner as 
compound 4a except that 3-pentanone was used Instead of cyclohexa- 
none. ‘HNMR CDCI, d 6.89 (m, 4H, Ar-H), 6.49 (d. J = 8.3 Hz, 2H, Ar-H), 
4.82 (s, 4H, -CH,-), 2.23 (s, 6H, Ar-CH,), 2.00 (q. J=7.3 Hz, 4H, - 
CH,CH,), 1.23 (s, 18H,(t-but), 0.58 (t, J = 7.3 Hz, 6H, -CH,CH,). 
1’-[4-(2-0xo-3,3-dimethylbutoxy~-3-methylphenyl]-1’[4-(2,3- 
epoxypropoxy)-3-methylphenyllpentane 6 (LG190176) 
To 1 .O g (3.5 mmol) of the diol 3b in 10 ml dimethyl formamide (DMF) 
was added 8.4 mg (3 5 mmol) of Nat-l. After stirnng for 5 min, 471 mg 
(3.5 mmol) of chloropinacolone was added. The reaction mixture was 
stirred for a further 30 mrn followed by addition of H,O and then EtOAc. 
The organic layer was separated and washed (H,O, brine), dried 
(MgSO,), and concentrated. Three spots were observed by TLC and 
the desired product 5 corresponded to the middle spot. Purification by 
silica gel chromatography (10% EtOAc-90% hexanes) resulted in 250 mg 
(0.57 mmol) of 5 (16% yield). 
To 80mg (0.21 mmol) of 5 in 1 ml of dry DMF was added 5.5mg 
(0.23 mmol) of NaH. The mixture was stirred at room temperature for 
30 mm followed by addltton of 22.0 mg (0.23 mmol) of eplchlorohydrin. 
The reaction was heated at 120°C for 1 h or until complete by TLC 
(20% EtOAc 80% hexanes). Water was added followed by EtOAc. The 
organic layer was separated and washed (H,O, brine), dried (MgSO,), 
and concentrated. Purification by silica gel chromatography (10% 
EtOAc/SO% hexanes) resulted in 30 mg (0.07 mmol) of 6 as a clear oil 
(33% yield). ‘H NMR CDCI, d 6.89 (m, 4H, Ar-H), 6.66 (d, J = 8.3 Hz, 
1 H, Ar-H), 6.49 (d, J = 8.3 Hz, 1 H, Ar-H), 4.83 (s, 2H, -CH,-), 4.18 (dd, 
J = 11.3, J = 3.3 Hz, 1 H, -CH2-), 3.95 (dd, J = 11.3, J = 3.3 Hz, 1 H, 
CH2-), 3.35 (m, 1 H, -CH-). 2.90-2.76 (m, 2H, CH,), 2.23 (s, 3H, Ar- 
CH,), 2.18 (s, 3H, A&H,), 2.00 (q, J = 7.3 Hz, 4H, -Cff,CH,), 1.24 
(s, 18H,(t-but), 0.59 (t, J = 7.3 Hz, 6H, -CH,CH3). 
7‘-[4-(2-Hydroxy-3,3-dimethylbutoxy)-3-methylphenyl]-2’- 
14-(2,3-dihydroxypropoxy)-3-methylphenyl]pentane 8 
(LG190178) 
To 200 mg (0.52 mmol) of 5 in 4 ml of dry DMF was added 14.0 mg 
(0.58 mmol) of NaH and the mixture was stirred for 20 min. Glycidol 
(43.0 mg, 0.58 mmol) was added and the reaction was warmed to 
80°C for 1 h. The reactlon was poured into 1 :I EtOAc:hexane and the 
orgamc layer was separated, washed (H,O, brine), dried (MgSO,) and 
concentrated. Punflcatlon by silica gel chromatography (10% EtOAc- 
90% hexanes) resulted In 1 17 mg (0.26 mmol) of 7 (50% yield). 
To 70 mg (0.15 mmol) of 7 in 2.5 ml of MeOH at 0°C was added 5.7 mg 
(0.15 mmol) of NaBH,. After stirring for 20 min, the reaction was 
quenched with sat. NH,CI and the product was extracted with EtOAc. 
The organic layer was washed with H,O, then brine, dried (MgSO,), con- 
centrated and purified by silica gel chromatography to give 23 mg 
(0.05 mmol) of 8 as a clear 011 (33% yield). ‘H NMR CDCI, d 6.94 (m, 
4H, A#), 6.69 (d, J = 8.3 M, 2H, Ar-H), 4.12-4.02 (m, 4H), 3.88-3.67 
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(m, 4H), 2.17 (s, 3H, Ar-CH,), 2.16 (s, 3H, A&H,), 2.04 (q, J = 7.3 Hz, 
4H, -CH,CH,), 1 .OO (s, 9H, (t-but), 0.59 (t, J = 7.3 Hz, 6H, -CH,CH,). 
Cotransacfivation assays 
Hep G2 (human hepatoma, ATCC) cells were transfected with and 
without a human VDR expression vector (pRShVDR [28,35]) along with 
a reporter plasmid encoding luciferase driven by one copy of a VDRE 
sequence from the h24(OH)ase promoter (VDRE(l)-AMlV-LUC [281). 
Transfections were performed in triplicate in 96-well gelatin-coated 
plates with 20 Fg DNA (0.5 ug receptor vector, 5 pg reporter plasmid, 
5 pg P-galactosidase plasmid and pGEM carrier DNA to 20 pg) per ml of 
CaPO,-Hepes buffer. Six hours later, 1,25(OH),D, (Solvay DuPhar) or 
various compounds were added to cells in concentrations from 1 O-r2- 
10m5 M and incubation was for 40 h. Cells were lysed and luciferase 
activities were normalized with P-galactosidase values to control for vari- 
able transfection efficiencies, as previously described [281. 
VDR in vitro ligand-binding assays 
Human VDR [35] was constructed into a yeast expression plasmid as 
described previously [361. Crude yeast cell protein extracts containing 
recombinantly-expressed hVDR (4 pg per tube) were utilized for com- 
petition ligand-binding assays using L3Hl-l ,25(OH),D, (Amersham). 
For equilibrium assays, incubation of protein extracts and ligands was 
for 16 h at 4°C. For nonequilibrium assays, VDR-containing yeast extract 
(2.5 pg per tube) was incubated with various compounds for 20 h at 
4°C prior to addition of 0.34 nM 13Hl-l ,25(OH),D, for time periods 
ranging from 2-60 min at 4°C. Separation of bound ligand from 
unbound ligand was achieved by use of hydroxylapatite resin as 
described previously [371. Equilibrium competition analyses utilized 
[3Hl-1,25(OH),D3 at 2 nM and concentrations of invented compounds 
from 0.1 nM to 10 PM. Binding buffer for both types of assays con- 
tained 10 mM Tris, pH 7.5, 1 mM DTT and 0.4 M KCI and wash buffer 
contained 10 mM Tris, 7.5, 0.1 M KCI and 10 mM CHAPS. 
Cancer cell growth inhibition assays and analysis 
SK-BR-3 human breast cancer cells (ATCC) and LNCaP human 
prostate cancer cells (ATCC) were plated in 96-well flat-bottomed 
plates in 50 pl serum-containing media/well. All cell growth assays 
were carried out in media containing 5-7.5% FBS. Cell plating 
numbers (cells per well) were as follows: SK-BR-3-3000 and LNCaP- 
1000, and allowed to adhere for 24 h prior to compound addition. 
Tenfold serial dilutions of compounds were performed with changing of 
pipette tips between each dilution and then were added to cells (50 1-11 
per well) to final concentrations of 1 x 1 O-5 M to 1 x 10-j’ M, (1% 
ethanol), in triplicate. Cells and ligands were incubated at 37°C for 3 
(SK-BR-3) or 4 (LNCaP) days. BrdU (5-bromo-2’-deoxyuridine) incor- 
poration was analyzed as a measure of DNA replication (Cell Prolifera- 
tion ELISA kit, Boehringer) and absorbance was measured at 450 nm. 
One row of wells contained media only and these absorbance values 
were averaged as background and subtracted from absorbance values 
from each well containing cells. Efficacy (Yo growth inhibition) was 
determined as [l-(0.0. at maximal response with compoundl0.D. of 
average vehicle) x 1 001. Potency (EC,,) values were determined as the 
concentration of compound that elicited a half maximal response. 
Leukemic cell differentiation 
HL60 human promyelocytic leukemia cells (ATCC) were grown in media 
containing 150/, FBS and plated at 100,000 cells/ml in 10 cm dishes or 
in six-well plates. Ligands were added in ethanol vehicle (1%) at various 
concentrations for 5 days without changing the media. On the fifth day, 
cells were harvested and assayed for markers of differentiation. Cells 
that bioreduced nitroblue tetrazolium (NBT) turned blue-black and rep- 
resented differentiated cells [30], whereas undifferentiated cells were 
colorless. Cells were counted and percent differentiated cells were 
determined from the two numbers. The macrophage-specific cell surface 
protein marker, CD14, was assayed for by use of a fluorescent dye 
tagged anti-CD14 antibody (Becton Dickinson) and FACS analyses 
[311. EC,, values represent the concentration of ligand that induced 
50% of the cells to be NBT formazan-positive or CD1 4-positive. 
Keratinocyte assays 
Normal human epidermal keratinocytes (NHEK) were grown according 
to vendor specifications (Clonetics, San Diego). BrdU assays were 
performed as above except that cells were plated at 200 cells per well 
(96-well plates) and treatment with ligands (10-5-10-1’ M) was for 
3 days. For cell staining, 30,000 cells per well were plated in six well 
plates. Fresh media with ligands was added on day 0, day 2 and day 4. 
On day 7, cells were washed with PBS, fixed and photographed. 
DBP-binding assay 
DBP competition binding assays were done as performed previously 
[27,34] using human serum (Scantibodies) or rat serum (Gibco-BRL) 
as sources of DBP diluted 1 :lO,OOO in sodium phosphate buffer 
(pH 7.4). Sera were incubated with 2 nM L3Hl-25(OH)D, (Amersham) 
with and without unlabeled 25(OH)D, or 1,25(OH),D, in concentra- 
tions ranging from 0.01 nM to 1 uM, or unlabeled vitamin D mimic com- 
pounds ranging from 10 nM to 10 pM, for 2 h at 4°C. Separation of 
bound from unbound ligand was achieved by the use of Dextran- 
coated charcoal in gelatin phosphate buffer. 
In vivo gene regulation and calcium potential 
Balblc mice (Harlan Sprague-Dawley; female, 10 weeks, -19 g (3 day 
study), male, 8 weeks, -22 g (5 day study)) were housed under normal 
lighting and received a vitamin-D-deficient, calcium-replete diet (Purina 
Mills #5826-C-L) and water ad /hiturn for 7 days prior to initiation of 
treatment with compounds. Mice were housed in a U.S. Department of 
Agriculture-registered facility in accordance with NIH guidelines for the 
care and use of laboratory animals. Compounds were administered in 
sesame oil vehicle with 4% ethanol by oral gavage (dose volume 
0.1 ml). Dosing was everyday for 3-5days (3-4 animals per dosing 
group). On the final day of dosing, 4-6 h after the last dose, animals 
were euthanized, blood and kidneys were removed. Serum was pre- 
pared and calcium determinations were done by use of a calorimetric 
assay (Sigma). 15-20 pg total kidney RNA was utilized in Northern blot 
analysis using a rat 24(OH)ase probe; a GAPDH probe was used to 
normalize for RNA loading, as described previously [38]. Cuantitation 
was by Phosphorlmager analysis. 
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